SEC Tracker
Get the app

GRAIL GRAL

GRAIL (GRAL) filed its Q3 2025 Form 10-Q, providing investors with an update on the company's financial performance and operational activities during the quarter. The filing highlights GRAIL's continued progress in developing its innovative cancer detection technology, which is expected to drive long-term growth and shareholder value. Investors will want to closely review the report to assess GRAIL's near-term financial health and prospects for future success in the rapidly evolving diagnostics market.

Form
10-Q
Filed
Importance
Notable

Open in the appGet the appView on EDGAR

Get an email when GRAIL files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 8071 and related industry codes: the same peer list as the financial tables.

  1. Veracyte VCYT public float $1.7B, Jun 30, 2025
  2. CareDx CDNA public float $1.0B, Jun 30, 2025
  3. Caris Life Sciences CAI public float $3.9B, Jun 30, 2025
  4. RadNet RDNT public float $4.1B, Jun 30, 2025
  5. Guardant Health GH public float $6.2B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.